Core Viewpoint - The stock of Shuyou Shen experienced a decline of 2.02% on November 19, with a trading price of 34.02 CNY per share, reflecting a significant drop in recent trading days despite a substantial year-to-date increase of 359.11% [1] Company Overview - Shuyou Shen (Beijing) Biopharmaceutical Co., Ltd. is primarily engaged in the research, production, and sales of biological products and some chemical drugs, with its main revenue sources being the injection of mouse nerve growth factor (Sutai) at 59.17%, compound polyethylene glycol electrolyte powder at 33.19%, and others at 7.63% [1] - The company was established on August 16, 2002, and went public on April 15, 2011 [1] Financial Performance - For the period from January to September 2025, Shuyou Shen reported an operating income of 181 million CNY, a year-on-year decrease of 30.82%, and a net profit attributable to shareholders of -30.69 million CNY, a decline of 227.71% [2] - The company has cumulatively distributed 771 million CNY in dividends since its A-share listing, with no dividends paid in the last three years [3] Shareholder Structure - As of September 30, 2025, the number of shareholders increased to 46,500, a rise of 46.97%, while the average circulating shares per person decreased by 31.98% to 9,745 shares [2] - Among the top ten circulating shareholders, notable changes include a decrease in holdings by the third-largest shareholder, Xingquan Helun Mixed A, by 3.45 million shares, and an increase in holdings by the fifth-largest shareholder, Xingquan Heyi Mixed A, by 338,750 shares [3] Market Activity - The stock has seen significant trading activity, with a net outflow of 29.42 million CNY from major funds on November 19, and it has appeared on the trading leaderboard eight times this year, with the most recent instance on October 31, where it recorded a net buy of 373 million CNY [1]

截至11月17日收盘，创新药概念下跌1.72%，位居概念板块跌幅榜前列，板块内，科兴制药、舒泰神、 昂利康等跌幅居前，股价上涨的有33只，涨幅居前的有富祥药业、海南海药、百花医药等，分别上涨 12.14%、10.04%、8.63%。 | 603858 | 步长制药 | -2.89 | 0.96 | -906.39 | | --- | --- | --- | --- | --- | | 301075 | 多瑞医药 | -2.17 | 1.99 | -894.32 | | 301408 | 华人健康 | -2.92 | 22.50 | -887.82 | | 600479 | 千金药业 | -1.90 | 1.87 | -871.50 | | 000597 | 东北制药 | -1.54 | 1.20 | -835.15 | | 002099 | 海翔药业 | 1.1 1 | 1.30 | -831.28 | | 301333 | 诺思格 | -1.53 | 3.36 | -788.71 | | 300575 | 中旗股份 | 0.15 | 2.31 | -781.84 | | 300026 | 红日药业 | -1 ...

Group 1 - The cell immunotherapy sector experienced a decline of 1.87%, ranking among the top losers in the concept sector, with companies like Shutaishen, Jimin Health, and Puris leading the declines [1][2] - Among the concept stocks, Baohua Pharmaceutical, ST Zhongzhu, and Laimei Pharmaceutical saw the highest gains, with increases of 8.63%, 4.80%, and 0.93% respectively [1][3] - The cell immunotherapy sector faced a net outflow of 1.658 billion yuan, with 54 stocks experiencing net outflows, and 8 stocks seeing outflows exceeding 50 million yuan [1][2] Group 2 - The top net outflow stocks in the cell immunotherapy sector included Shutaishen with a net outflow of 284.46 million yuan, followed by Hengrui Medicine, Hanyu Pharmaceutical, and Fosun Pharmaceutical with outflows of 236.06 million yuan, 124.39 million yuan, and 104.04 million yuan respectively [1][2] - Conversely, the stocks with the highest net inflows included Baohua Pharmaceutical, Boji Pharmaceutical, and Yuekang Pharmaceutical, with inflows of 79.05 million yuan, 13.46 million yuan, and 4.04 million yuan respectively [1][3] - The trading volume for Shutaishen was 12.35%, indicating significant trading activity despite the decline in stock price [2][3]

Market Overview - The chemical pharmaceutical sector experienced a decline of 1.44% on November 17, with Shuyatong leading the drop [1] - The Shanghai Composite Index closed at 3972.03, down 0.46%, while the Shenzhen Component Index closed at 13202.0, down 0.11% [1] Top Gainers in Chemical Pharmaceutical Sector - Fuxiang Pharmaceutical (300497) saw a closing price of 21.15, with a significant increase of 12.14% and a trading volume of 1.8867 million shares, amounting to a transaction value of 3.8 billion [1] - Muanhai Pharmaceutical (000566) closed at 7.45, up 10.04%, with a trading volume of 2.5684 million shares, totaling 1.871 billion [1] - Kangzhiyue Pharmaceutical (300086) closed at 11.11, increasing by 4.61%, with a trading volume of 1.5735 million shares, amounting to 1.747 billion [1] Top Losers in Chemical Pharmaceutical Sector - Buzou Pharmaceutical (300204) closed at 36.31, down 7.61%, with a trading volume of 560,200 shares, resulting in a transaction value of 2.067 billion [2] - Anglikang (002940) closed at 43.43, decreasing by 7.60%, with a trading volume of 251,600 shares, totaling 1.112 billion [2] - Aozhu Pharmaceutical (002755) closed at 18.59, down 5.59%, with a trading volume of 260,100 shares, amounting to 489 million [2] Capital Flow Analysis - The chemical pharmaceutical sector experienced a net outflow of 3.72 billion from institutional investors, while retail investors saw a net inflow of 2.604 billion [2] - The sector's overall capital flow indicates a mixed sentiment, with institutional investors withdrawing funds while retail investors are actively buying [2] Individual Stock Capital Flow - Jingxin Pharmaceutical (002020) had a net inflow of 21.78 million from institutional investors, while retail investors experienced a net outflow of 13.49 million [3] - Taiankang (301263) saw a net inflow of 13.83 million from institutional investors, with retail investors facing a net outflow of 26.79 million [3] - Meinuohua (603538) recorded a net inflow of 12.13 million from institutional investors, while retail investors had a net outflow of 17.35 million [3]

Core Viewpoint - The company Shuyou Shen (300204) has its conditional listing application for the injectable STSP-0601 accepted by the National Medical Products Administration (NMPA) in June 2025, currently undergoing the normal review process [1] Group 1 - The priority review and approval process for the listing registration application has a review time limit of 130 days [1] - Preliminary reviews by various professional departments have been completed, and the process has entered the next stage, indicating that the review is progressing normally [1] - The review and approval for STSP-0601 has not concluded, and updates on research and development projects will be provided in future regular reports and project progress announcements [1]

Core Viewpoint - The company Shutaishen (300204.SZ) has submitted a conditional listing application for its injectable STSP-0601, which was accepted by the National Medical Products Administration (NMPA) in June 2025 and is currently undergoing the normal review process [1] Group 1 - The priority review application for STSP-0601 has a review timeline of 130 days [1] - Preliminary reviews by various professional departments have been completed, and the application has entered the next stage [1] - The timing for the Center for Drug Evaluation (CDE) is currently paused, indicating that the review process is proceeding normally and has not concluded [1]

Core Points - The company Shuotai Shen (300204.SZ) has provided an update regarding the conditional listing application for its injectable STSP-0601, which was accepted by the National Medical Products Administration (NMPA) in June 2025 and is currently undergoing the normal review process [2] - The priority review timeline for the listing registration application is set at 130 days, and the preliminary review by various professional departments has been completed, leading to a temporary suspension of the CDE's timing, which is part of the normal review process [2] - The review and approval process for STSP-0601 has not concluded, and stakeholders are encouraged to monitor future regular reports and project progress announcements for updates [2]

Core Viewpoint - The stock of Shuyou Shen has shown significant volatility, with a year-to-date increase of 426.05%, but recent performance indicates a mixed trend with a decline over the past 60 days [2]. Group 1: Stock Performance - As of November 14, Shuyou Shen's stock price rose by 2.04% to 38.98 CNY per share, with a trading volume of 9.15 billion CNY and a market capitalization of 186.24 billion CNY [1]. - The stock has experienced a 14.71% increase over the last five trading days, but a 2.31% decrease over the last 20 days and a 23.54% decline over the last 60 days [2]. Group 2: Financial Performance - For the period from January to September 2025, Shuyou Shen reported a revenue of 181 million CNY, a year-on-year decrease of 30.82%, and a net profit attributable to shareholders of -30.69 million CNY, a decrease of 227.71% [2]. - The company has not distributed any dividends in the last three years, with a total payout of 771 million CNY since its A-share listing [3]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders increased by 46.97% to 46,500, while the average circulating shares per person decreased by 31.98% to 9,745 shares [2]. - Among the top ten circulating shareholders, notable changes include a decrease in holdings by Xingquan Helun Mixed A and an increase by Xingquan Heyi Mixed A [3].

Core Insights - Shuyou Shen's stock price increased by 5.08% on November 13, reaching 39.12 CNY per share, with a trading volume of 1.698 billion CNY and a turnover rate of 10.05%, resulting in a total market capitalization of 18.69 billion CNY [1] - The stock has risen for three consecutive days, with a cumulative increase of 9.56% during this period [1] Company Overview - Shuyou Shen (Beijing) Biopharmaceutical Co., Ltd. was established on August 16, 2002, and went public on April 15, 2011 [1] - The company primarily engages in the research, production, and sales of biological products and some chemical drugs [1] - Main revenue sources include: 59.17% from injectable mouse nerve growth factor (Sutai Shen), 33.19% from compound polyethylene glycol electrolyte powder, and 7.63% from other products [1] Fund Holdings - CITIC Prudential Fund holds a significant position in Shuyou Shen, with the CITIC Prudential Zhi Rui Mixed A Fund (003432) owning 295,000 shares, accounting for 3.99% of the fund's net value, making it the eighth-largest holding [2] - The fund has realized a floating profit of approximately 557,600 CNY today and 958,800 CNY during the three-day increase [2] Fund Manager Performance - The fund manager Wang Rui has a tenure of 10 years and 201 days, with a total fund size of 6.438 billion CNY and a best return of 253.09% during his tenure [3] - Liu Hongliang has been managing the fund for 1 year and 121 days, with a fund size of 2.693 billion CNY and a best return of 9.67% [3] - Zhu Huiling has a shorter tenure of 226 days, managing a fund size of 259 million CNY, with a best return of 8.63% [3]

Group 1 - The core viewpoint of the news is that Shuotai Shen's stock price increased by 5.66%, reaching 39.00 CNY per share, with a trading volume of 1.576 billion CNY and a turnover rate of 9.24%, resulting in a total market capitalization of 18.633 billion CNY [1] - Shuotai Shen (Beijing) Biopharmaceutical Co., Ltd. was established on August 16, 2002, and went public on April 15, 2011. The company primarily engages in the research, production, and sales of biological products and some chemical drugs [1] - The main revenue composition of Shuotai Shen includes: 59.17% from injectable mouse nerve growth factor (Sutai), 33.19% from compound polyethylene glycol electrolyte powder, and 7.63% from other products [1] Group 2 - From the perspective of the top ten holdings of funds, the Dongfang Alpha Fund has a significant position in Shuotai Shen, with the Dongfang Alpha Health Industry Mixed Fund A (024357) increasing its holdings by 223,000 shares, totaling 239,500 shares, which accounts for 6.08% of the fund's net value, ranking as the eighth largest holding [2] - The Dongfang Alpha Health Industry Mixed Fund A (024357) was established on June 12, 2025, with a latest scale of 35.3951 million CNY. Since its inception, it has experienced a loss of 3.88% [2] - The fund manager of Dongfang Alpha Health Industry Mixed Fund A is Meng Yu, who has been in the position for 1 year and 350 days, with total assets of 306 million CNY. The best fund return during his tenure is 18.12%, while the worst return is -4.04% [2]